3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Precise Poly(ADP-ribose) Polymerase Inhibition

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a highly selective poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 of ~50 nM in CHO cells, facilitating >95% PARP inhibition at ≥1 μM without notable toxicity (APExBIO). It improves endothelial function post-oxidative stress by enhancing nitric oxide-mediated vasorelaxation (hydrogen peroxide models) (Grunewald et al., 2019). In diabetic mouse models, it reduces albuminuria, mesangial expansion, and podocyte depletion, supporting its utility in diabetic nephropathy research. The compound is water-soluble at ≥23.45 mg/mL (ultrasonic assistance) and stable at -20°C. APExBIO provides this reagent for research use, ensuring consistent performance in advanced PARP inhibition workflows.

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes catalyzing ADP-ribosylation, a post-translational modification critical for DNA repair, cellular stress responses, and the regulation of innate immunity (Grunewald et al., 2019). Humans encode 17 PARPs, with PARP1 and PARP2 being central to poly(ADP-ribosyl)ation (PARylation) processes. Dysregulation of PARP activity is linked to pathological conditions including oxidative stress-induced myocyte dysfunction and diabetic nephropathy. Inhibiting PARP activity has emerged as a strategy to dissect these pathways and mitigate cellular injury in experimental models. 3-Aminobenzamide (PARP-IN-1), as supplied by APExBIO, offers a precise means to modulate PARP activity and study downstream effects in a range of biological contexts (see mechanistic overview; this article extends mechanistic foundations by detailing benchmarking data in disease models).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide acts as a competitive inhibitor of the NAD⁺ binding site of PARP enzymes. By occupying the catalytic domain, it prevents the transfer of ADP-ribose units to target proteins, effectively blocking PARylation. This inhibition is highly potent, with an IC50 of approximately 50 nM measured in CHO cell assays (APExBIO technical data). At concentrations above 1 μM, 3-Aminobenzamide achieves greater than 95% inhibition of PARP activity with minimal cytotoxicity observed in standard cell viability assays. The compound’s efficacy extends to both DNA-damage response and inflammatory signaling pathways, as PARP1 and PARP2 are critical mediators in these processes. In oxidative stress models, inhibition of PARP reduces NAD⁺ consumption, preserves cellular ATP, and prevents cell death secondary to energy failure. The selectivity profile of 3-Aminobenzamide is well characterized, with minimal off-target activity at recommended concentrations, supporting its use in mechanistic and translational research (robust inhibition profile contrasted here; this article provides updated cross-assay solubility and toxicity benchmarks).

Evidence & Benchmarks

• 3-Aminobenzamide inhibits PARP with an IC50 of ~50 nM in CHO cells, demonstrating high potency in cellular systems (APExBIO).
• At ≥1 μM, the compound achieves >95% inhibition of PARP enzymatic activity in vitro without significant toxicity to cell lines tested (APExBIO).
• PARP inhibition by 3-Aminobenzamide improves endothelium-dependent, nitric oxide-mediated vasorelaxation following oxidative stress induced by hydrogen peroxide (Grunewald et al., 2019).
• In diabetic db/db (Lepr db/db) mouse models, 3-Aminobenzamide reduces albumin excretion, mesangial expansion, and podocyte depletion, highlighting its value in diabetic nephropathy research (Grunewald et al., 2019).
• The compound is water-soluble at ≥23.45 mg/mL (ultrasonic assistance), ethanol-soluble at ≥48.1 mg/mL, and DMSO-soluble at ≥7.35 mg/mL, allowing flexible integration into diverse experimental protocols (APExBIO).
• PARP inhibition in macrophage infection models enhances viral replication and suppresses interferon production in certain viral mutants, evidencing a role in host-virus interactions (Grunewald et al., 2019).
• Long-term solution storage is not recommended due to gradual loss of activity; powder should be stored at -20°C for optimal stability (APExBIO).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is deployed in multiple research domains:

• Oxidative Stress Models: Used to dissect pathways of oxidant-induced myocyte and endothelial dysfunction.
• Diabetic Nephropathy: Applied in rodent models to evaluate mechanisms and interventions for kidney injury.
• PARP Activity Assays: Gold-standard reagent for in vitro and cell-based measurement of PARP inhibition.
• Viral Immunology: Employed to interrogate PARP-mediated restriction of viral replication and modulation of interferon responses (see how this extends host-virus interaction analysis).

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not recommended for diagnostic or therapeutic applications in humans; it is designated for research use only (APExBIO).
• It does not inhibit non-PARP ADP-ribosyltransferases (e.g., ARTCs, sirtuins) at standard working concentrations, limiting its utility to poly(ADP-ribose) polymerase-specific studies (Grunewald et al., 2019).
• Long-term solution storage (>1 week) at room temperature or 4°C leads to decreased inhibitor potency; always prepare fresh aliquots.
• At concentrations above the recommended range, off-target effects or cellular toxicity may occur—do not exceed validated dosing protocols.
• In vivo application data are primarily preclinical; efficacy and safety in clinical settings remain unestablished (see preclinical focus).

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1) is supplied as a solid (molecular weight 136.15, formula C7H8N2O, CAS 3544-24-9) and can be reconstituted in water, ethanol, or DMSO with ultrasonic assistance to achieve desired working concentrations. Aliquots should be prepared and stored at -20°C to preserve activity. For in vitro assays, concentrations of 50 nM to 1 μM are typical for potent, selective PARP inhibition. In cell-based models, titration to determine minimal effective dose is advised to minimize off-target effects. Shipping is performed on blue ice to maintain compound integrity. For advanced troubleshooting and workflow optimization, see workflow strategies; this article adds explicit solubility and storage guidance for reproducibility.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) is established as a potent, reliable PARP inhibitor for dissecting poly(ADP-ribose) polymerase biology across diverse experimental systems. Its low toxicity profile, flexible solubility, and robust performance in validated models support its ongoing use in research on DNA repair, oxidative stress, metabolic disease, and viral immunology. Continued benchmarking and expansion into emerging models will further clarify its translational potential. For more information or to purchase, visit the official APExBIO product page.